Earlier this year, UNC-Chapel Hill and GlaxoSmithKline (GSK), a global, research-based pharmaceutical and health care company, announced our public-private partnership to zero in on what used to be perceived as an impossible task: finding a cure for AIDS.

This new venture comes after significant progress at the UNC School of Medicine and GSK to develop successful treatment options for HIV/AIDS. Qura Therapeutics, the new company we are partnering to create, will manage the business side of the new venture. The HIV Cure Center will serve as the hub of all of our AIDS research and will be located on our campus.

At UNC Health Care, we believe that smart, forward-looking and innovative partnerships are the key to a successful future in health care. The HIV Cure Center is one of those partnerships.

After 30 years of developing treatments at UNC, we see this joint venture as a tremendous step in tackling one of the most challenging health care problems of our time.

To learn more about Qura Therapeutics and the HIV Cure Center, click here.